Showing results (31-40 of 681) with videos related to
Sort By:
Pageof 69
Leukemia & Lymphoma|April 21, 2023
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacyNaveen Pemmaraju, Prithviraj Bose, Raajit Rampal, et al.Clinical Case Reports|January 30, 2018
Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposureAhmad Alhuraiji, Kiran Naqvi, Yang O Huh, et al.Acta Haematologica|September 12, 2023
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More YearsLucia Masarova, Prithviraj Bose, Naveen Pemmaraju, et al.European Journal of Haematology|December 12, 2017
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosisLucia Masarova, Ahmad Alhuraiji, Prithviraj Bose, et al.Leukemia & Lymphoma|August 6, 2016
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical studyKiran Naqvi, Naval Daver, Naveen Pemmaraju, et al.Clinical Lymphoma, Myeloma & Leukemia|February 8, 2021
Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib TherapyLucia Masarova, Prithviraj Bose, Naveen Pemmaraju, et al.Clinical Advances in Hematology & Oncology : H&O|December 9, 2016
Highlights in polycythemia vera from the 2016 EHA congressSrdan VerstovsekPostgraduate Medicine|February 9, 2013
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosisSrdan VerstovsekHematology. American Society of Hematology. Education Program|December 17, 2009
Therapeutic potential of JAK2 inhibitorsSrdan VerstovsekAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Therapeutic advances in myeloproliferative neoplasms: the role of new-small molecule inhibitorsSrdan VerstovsekPageof 69